Antitrust Antitrust

US FTC’s Section 13(b) powers must be restored to tackle anticompetitive drug pricing practices, senators told

By Khushita Vasant
  • 05 May 2022 23:19
  • 06 May 2022 00:25
The Federal Trade Commission must act to combat anticompetitive drug pricing practices by pharmacy benefit managers in the US, senators were told today. Congress also must pass laws that restore the agency’s powers to collect monetary redress for consumers, experts testified at a commerce committee panel hearing.

The Subcommittee on Consumer Protection, Product

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments


Latest News